The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study
In this heavily pretreated cohort of advanced NSCLC patients, cadonilimab-based regimens showed moderate antitumor efficacy with a generally tolerable and manageable safety profile. However, more evidence is needed to support the administration of cadonilimab in NSCLC patients refractory to previous anti-PD-1/PD-L1 therapy.
Authors
- Chengming Li (ORCID: https://orcid.org/0000-0003-4401-6007)
- Hongchang Shen
- Wen Zhao (ORCID: https://orcid.org/0000-0003-1077-4424)
- Jun Wang (ORCID: https://orcid.org/0000-0003-3941-2507)
- Chengjun Wang (ORCID: https://orcid.org/0000-0003-3167-3673)
- Hongxin Li (ORCID: https://orcid.org/0000-0003-4940-1414)
- Jisheng Li (ORCID: https://orcid.org/0000-0002-4186-6228)
- Xue Meng (ORCID: https://orcid.org/0000-0001-7925-7295)
- Chunyan Han (ORCID: https://orcid.org/0000-0002-0030-9839)
- Meiying Li (ORCID: https://orcid.org/0000-0003-4802-5859)
- Shuwen Yu (ORCID: https://orcid.org/0009-0006-4226-6239)
- Cuihua Yi
- Lian Liu
Institutions
- Shandong University (CN)
- Shandong Tumor Hospital (CN)
- Shandong Provincial Hospital (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Affiliated Hospital of Shandong Academy of Medical Sciences (CN)
- Qilu Hospital of Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1111/1759-7714.15455
- Citations
- 14
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.96
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province